Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Thermo Fisher Scientific Inc. (TMO), covering cash flow, earnings, and balance sheets.
Thermo Fisher Scientific Inc. (TMO) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Thermo Fisher Scientific Inc. TMO financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $10.36B | $11.39B | $10.60B | $10.54B |
| Cost of Revenue | $6.13B | $6.47B | $6.27B | $6.20B |
| Gross Profit | $4.24B | $4.92B | $4.33B | $4.34B |
| Gross Profit Ratio | $0.41 | $0.43 | $0.41 | $0.41 |
| R&D Expenses | $342.00M | $374.00M | $346.00M | $339.00M |
| SG&A Expenses | $2.08B | $2.08B | $2.10B | $2.25B |
| Operating Expenses | $2.52B | $2.89B | $2.49B | $2.59B |
| Total Costs & Expenses | $8.65B | $9.38B | $8.76B | $8.78B |
| Interest Income | $203.00M | $227.00M | $277.00M | $295.00M |
| Interest Expense | $303.00M | $317.00M | $356.00M | $354.00M |
| Depreciation & Amortization | $399.00M | $742.00M | $740.00M | $790.00M |
| EBITDA | $1.72B | $3.00B | $2.91B | $2.98B |
| EBITDA Ratio | $0.17 | $0.26 | $0.27 | $0.28 |
| Operating Income | $1.72B | $2.02B | $1.84B | $1.76B |
| Operating Income Ratio | $0.17 | $0.18 | $0.17 | $0.17 |
| Other Income/Expenses (Net) | -$96.00M | -$75.00M | -$96.00M | -$55.00M |
| Income Before Tax | $1.62B | $1.94B | $1.74B | $1.76B |
| Income Before Tax Ratio | $0.16 | $0.17 | $0.16 | $0.17 |
| Income Tax Expense | $95.00M | $150.00M | $99.00M | $128.00M |
| Net Income | $1.51B | $1.83B | $1.63B | $1.55B |
| Net Income Ratio | $0.15 | $0.16 | $0.15 | $0.15 |
| EPS | $3.99 | $4.79 | $4.27 | $4.05 |
| Diluted EPS | $3.98 | $4.78 | $4.24 | $4.04 |
| Weighted Avg Shares Outstanding | $378.00M | $382.85M | $382.00M | $382.00M |
| Weighted Avg Shares Outstanding (Diluted) | $379.00M | $383.00M | $384.00M | $383.00M |
The company's financials show resilient growth, with revenue advancing from $10.54B in Q2 2024 to $10.36B in Q1 2025. Gross profit remained healthy with margins at 41% in Q1 2025 compared to 41% in Q2 2024. Operating income hit $1.72B last quarter, sustaining a consistent 17% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $1.72B. Net income dropped to $1.51B, while earnings per share reached $3.99. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan